http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#Head http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#assertion http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#provenance http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#pubinfo http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00065 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association http://www.w3.org/2000/01/rdf-schema#label renflexis is a tumor necrosis factor tnf blocker indicated for crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 1 reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease 1 1 pediatric crohn s disease reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 2 ulcerative colitis reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 3 pediatric ulcerative colitis reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy 1 4 rheumatoid arthritis in combination with methotrexate reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease 1 5 ankylosing spondylitis reducing signs and symptoms in patients with active disease 1 6 psoriatic arthritis reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function 1 7 plaque psoriasis treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate 1 8 renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing crohn s disease renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active crohn s disease who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms inducing and maintaining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy renflexis in combination with methotrexate is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active rheumatoid arthritis renflexis is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis renflexis is indicated for reducing signs and symptoms of active arthritis inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis renflexis is indicated for the treatment of adult patients with chronic severe i e extensive and or disabling plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate renflexis should only be administered to patients who will be closely monitored and have regular follow up visits with a physician see boxed warnings warnings and precautions 5 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00065 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#provenance http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#pubinfo http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#sig http://purl.org/nanopub/x/hasSignature dOm5/WAv5BgXt+IYi4vLyh2TE0NFHd3/RCtdl2dU5gaUCDjFda8dhrHelRQxrfEeq9wkloVeS019xgDqH1wao056jMXuKMlqLf9QFVuFdTYW9s97gYorC5Qu9PbUI3Yn8pNLOln6LLkXa1g7ayRkb4J+VlWmmjUpCIa0pE7oDnk= http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://purl.org/dc/terms/created 2021-07-03T15:17:24.207+02:00 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAO4ZftZuVmtKAi5g0V0-nFkfZpZvXT-mZMnr3qvNDO40 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs